← All companies

AKBA

Akebia Therapeutics, Inc.

AKBA Nasdaq Pharmaceutical Preparations EDGAR ↗

$1.32

+0.01 +0.76%

Key statistics

from XBRL data in SEC filings

Market cap

$354M

Revenue (TTM)

$232M

Net income (TTM)

-$20.5M

EPS (TTM)

$-0.08

P/E ratio

—

Dividend yield

—

Free cash flow

$67.7M

Cash

$163M

Total assets

$363M

Gross margin

—

52-week range

$0.82 – $3.79

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Regulation FD disclosure; Other events Jun 30, 2026 8-K Shareholder vote results Jun 22, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 8-K Director or officer change Apr 1, 2026 10-K Fiscal year ended 2025-12-31 Feb 26, 2026 8-K Results of operations (earnings release) Feb 26, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Director or officer change Jan 30, 2026 8-K Results of operations (earnings release); Regulation FD disclosure Jan 12, 2026 8-K Entered a material agreement; Regulation FD disclosure; Other events Dec 1, 2025 8-K Entered a material agreement Nov 17, 2025 10-Q Quarter ended 2025-09-30 Nov 10, 2025 8-K Results of operations (earnings release) Nov 10, 2025 8-K Regulation FD disclosure; Other events Oct 28, 2025 10-Q Quarter ended 2025-06-30 Aug 7, 2025 8-K Results of operations (earnings release) Aug 7, 2025 8-K Director or officer change; Shareholder vote results Jun 13, 2025 10-Q Quarter ended 2025-03-31 May 8, 2025 8-K Results of operations (earnings release) May 8, 2025 8-K Entered a material agreement; Regulation FD disclosure; Other events Mar 20, 2025 10-K Fiscal year ended 2024-12-31 Mar 13, 2025 8-K Results of operations (earnings release) Mar 13, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Feb 7, 2025 8-K Regulation FD disclosure; Other events Jan 13, 2025 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Results of operations (earnings release) Nov 7, 2024 8-K Regulation FD disclosure Oct 22, 2024 8-K Entered a material agreement Oct 16, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Entered a material agreement; Terminated a material agreement Jul 11, 2024 8-K Director or officer change Jun 24, 2024 8-K Shareholder vote results Jun 10, 2024 10-Q Quarter ended 2024-03-31 May 9, 2024 8-K Results of operations (earnings release) May 9, 2024 8-K Took on a direct financial obligation Apr 23, 2024 8-K Entered a material agreement Apr 16, 2024 8-K Regulation FD disclosure; Other events Mar 28, 2024 8-K Director or officer change Mar 15, 2024 10-K Fiscal year ended 2023-12-31 Mar 14, 2024